Basic and Clinical Research Programs |
|
Dear Program Members,
For the past 6 months, our region (and indeed, the world) has had to mitigate the staggering impact of COVID-19 on all aspects of life. Some research/programmatic functions had to be significantly slowed, while others such as this newsletter had to be put on a temporary hiatus. Rutgers Cancer Institute of New Jersey’s commitment to conducting innovative cancer research and providing exemplary patient care remained constant.
We now embark on a “new normal” of Research Program meetings, scientific retreats, and other programmatic activities being offered entirely via virtual platforms. At the same time, we also move forward on initiatives to advance our research enterprise that we developed prior to the pandemic. For the foreseeable future, we will rely on online communication methods such as email communication, this newsletter, and the cancer institute’s website to keep you engaged and supported as cancer researchers. You are encouraged to reach out to me and your respective Program Leaders if you should have any questions or recommendations about the resources and services offered to Research Program Members.
Best Wishes,
Eileen White, PhD
Deputy Director, Chief Scientific Officer, and Associate Director for Basic Research
Rutgers Cancer Institute of New Jersey
|
|
2020 Virtual Program Meetings |
|
Program Meetings Carry On Despite COVID-19! |
|
Upcoming CMG Program Meetings:
11/18/20 @12:00pm: Alexander Ploss, PhD
12/16/20 @12:00pm: Danelle Devenport, MSc PhD
1/20/21 @12:00pm: Terri Wood, PhD
|
|
Upcoming CP Program Meetings:
11/24/20 @12:00pm: Matthew Moschitto, PhD
2/16/21 @12:00pm: Sagar Khare, PhD
3/16/21 @12:00pm: Zheng Shi, PhD
|
|
Upcoming CIPT Program Meetings:
11/2/20 @3:00pm: Howard Hochster, MD
12/14/20 @3:00pm: TBD
1/11/21 @3:00pm: TBD
2/1/21 @3:00pm: TBD
|
|
Upcoming GICG Program Meetings:
11/3/20 @12:00pm: Abdelfattah El Ouaamari, PhD
12/8/20 @12:00pm: Michael Levine, PhD
1/12/21 @12:00pm: Utz Herbig, PhD
|
|
Virtual Cancer Research Symposium |
|
November 20th, 2020 from 10:00am - 6:00pm |
|
Please join us for the inaugural Cancer Research Symposium jointly sponsored by the Rutgers Cancer Institute of New Jersey and Princeton University. The aim of this virtual symposium is to facilitate inter-institutional collaborations between researchers.
The agenda includes faculty presentations, trainee talks, and flash talks on posters selected from submitted abstracts.
Featured sessions focus on Cancer Genomics, Cancer Metabolism, Tumor Microenvironment, and Understanding and Addressing Cancer Burden.
Please reach out to Rutgers Cancer Institute Education & Training for questions: ed@cinj.rutgers.edu
|
|
Cancer Metabolism & Growth |
|
Alexander Ploss, PhD was awarded a NIAID grant entitled "Mechanisms of Hepatitis B Virus CCCDNA Formation" Grant Number: 1R01AI153236-01 Term: 05/15/2020 - 04/30/2025. Annual Direct Costs: $342,061
Gary Goldberg, PhD was awarded a NIH grant entitled "Targeting PDPN to prevent and combat oral cancer" Grant Number: 1R15CA235347-01 Term: 02/01/2019 - 01/31/2022. Annual Direct Costs: $298,091.
Jessie Yanxiang Guo, PhD was awarded a NIH grant entitled "Elucidate the mechanism of autophagy in supporting Lkb1-deficient lung tumorigenesis and metastasis" Grant Number: 1R01CA237347-01A1 Term: 02/01/2020 - 01/30/2025. Annual Direct Costs: $241,251.
|
|
Eileen White, PhD presented “Control of Cancer Metabolism and the Anti-cancer Immune Response by Autophagy” at the 107th Annual Meeting of Indian Science Congress Association held January 3-7, 2020 at University of Agricultural Sciences, Bangalore, India.
Eileen White, PhD presented “Role of Autophagy in Cancer Metabolism” at the AACR Special Conference on The Evolving Landscape of Cancer Modeling held March 2-5, 2020 in San Diego, California.
Eileen White, PhD presented “Role of Autophagy in Cancer Metabolism” at Cancer Metabolism and Signaling Symposium held April 17, 2020 via Teleconference.
Eileen White, PhD presented “Mitochondria and Cancer” at Mitochondria in Complex Diseases Symposium held April 21, 2020 via Teleconference.
Gary Goldberg, PhD presented "Cancer chemotherapy on the road to ruin and redemption" at Nagoya University held December 12, 2019 in Nagoya, Japan.
Gary Goldberg, PhD presented "PDPN is a culprit and a target for cell communication disorders leading to cancer and other diseases" at Nagoya University held December 13, 2019 in Nagoya, Japan.
|
|
Calianese DC, Birge RB. Biology of phosphatidylserine (PS): basic physiology and implications in immunology, infectious disease, and cancer. Cell Commun Signal. 2020;18(1):41. Epub 2020/03/13. doi: 10.1186/s12964-020-00543-8. PubMed PMID: 32160904; PMCID: PMC7065380.
Cao J, Yan, Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends in Cancer. Epub 2020 Mar 31.
Davra V, Saleh T, Geng K, Kimani S, Mehta D, Kasikara C, Smith B, Colangelo NW, Ciccarelli B, Li H, Azzam EI, Kalodimos CG, Birge RB, Kumar S. Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer. Mol Cancer Res. 2020;18(8):1189-201. Epub 2020/04/24. doi: 10.1158/1541-7786.Mcr-19-1144. PubMed PMID: 32321766.
Dragan M, Nguyen MU, Guzman S, Goertzen C, Brackstone M, Dhillo WS, Bech PR, Clarke S, Abbara A, Tuck AB, Hess DA, Pine SR, Zong WX, Wondisford FE, Su X, Babwah AV, Bhattacharya M. G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer. Cell Death Dis. 2020;11(2):106. Epub 2020/02/09. doi: 10.1038/s41419-020-2305-7. PubMed PMID: 32034133; PMCID: PMC7005685.
Ghergurovich JM, Esposito M, Chen Z, Wang JZ, Bhatt V, Lan T, White E, Kang Y, Guo JY, Rabinowitz JD. Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras-Driven Tumor Growth or Metastasis. Cancer Res. 2020;80(18):3820-9. Epub 2020/07/15. doi: 10.1158/0008-5472.Can-19-2486. PubMed PMID: 32661137; PMCID: PMC7501231.
Goldberg GS, Airley R. Cancer Chemotherapy: Basic Science to the Clinic: Wiley; 2020.
Li D, Ma Y, Liu W, Ren X, Chen M, Xu X, Sheng Z, Zhang K, Zhou R, Goodin S, Zheng X. Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures. Int J Med Sci. 2020;17(12):1795-802. Epub 2020/07/28. doi: 10.7150/ijms.47546. PubMed PMID: 32714082; PMCID: PMC7378654.
Liu J, Zhang C, Wu H, Sun X, Li Y, Huang S, Yue X, Shou-En L, Shen Z, Su X, White E, Haffty B, Hu W, Feng Z. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. The Journal of Clinical Investigation. 2020 May 18. Doi 10.1172/jci132876.
Pham K, Huynh D, Le L, Delitto D, Yang L, Huang J, Kang Y, Steinberg MB, Li J, Zhang L, Liu D, Tang MS, Liu C, Wang H. E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1. Cancer Lett. 2020. Epub 2020/08/24. doi: 10.1016/j.canlet.2020.08.010. PubMed PMID: 32829009.
Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Ther. 2020;27(6):438-47. Epub 2019/06/22. doi: 10.1038/s41417-019-0112-z. PubMed PMID: 31222182; PMCID: PMC6923616.
Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Front Oncol. 2019;9:1483. Epub 2020/01/31. doi: 10.3389/fonc.2019.01483. PubMed PMID: 31998643; PMCID: PMC6965158.
Yang CS, Luo P, Zeng Z, Wang H, Malafa M, Suh N. Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols. Mol Carcinog. 2020;59(4):365-89. Epub 2020/02/06. doi: 10.1002/mc.23160. PubMed PMID: 32017273; PMCID: PMC7255062.
Yang L, Garcia Canaveras JC, Chen Z, Wang L, Liang L, Jang C, Mayr JA, Zhang Z, Ghergurovich JM, Zhan L, Joshi S, Hu Z, McReynolds MR, Su X, White E, Morscher RJ, Rabinowitz JD. Serine Catabolism Feeds NADH when Respiration Is Impaired. Cell Metab. 2020 Apr 7;31(4):809-821.e6. doi: 10.1016/j.cmet.2020.02.017. Epub 2020 Mar 17. PMID: 32187526.
Yang Y, Karsli-Uzunbas G, Poillet-Perez L, Sawant A, Hu ZS, Zhao Y, Moore D, Hu W, White E. Autophagy promotes mammalian survival by suppressing oxidative stress and p53. Genes Dev. 2020 May 1;34(9-10):688-700. doi: 10.1101/gad.335570.119. Epub 2020 Mar 19. PMID: 32193353; PMCID: PMC7197357.
Yang Y, White E. Autophagy Suppresses TRP53/p53 and Oxidative Stress to Enable Mammalian Survival. Autophagy. 2020 May 5. doi: 10.1080/15548627.2020.1765522. Epub ahead of print. PMID: 32370647.
|
|
A Message from Dr. Burley and Dr. Zheng |
|
Cancer Pharmacology Program Members:
The past six months have been challenging for everyone due to the COVID-19 pandemic. Despite extraordinarily adverse conditions that limited our laboratory efforts and our interactions with one another, we are very proud of recent accomplishments by Cancer Pharmacology (CP) Program members in research, drug discovery, education, and funding highlighted in this newsletter. It is particularly noteworthy that a number of CP Program members stepped up to help lead Rutgers’ efforts in the fight against COVID-19 in fundamental research and therapeutics discovery. Our work will help strengthen Rutgers position as a national and international leader.
As we move forward under the Rutgers ‘Return to Research Plan’, we will continue using online resources to sustain and enhance communications within the CP Program and with other RCINJ research, clinical, population science, and community programs. We are optimistic that many of the newly announced RCINJ initiatives will enhance our ability to carry out cutting edge research, translate our laboratory findings to the clinic, and strengthen our impact on catchment area-related research.
Thank you much for your unwavering commitment to cancer research during these difficult times. We look forward to hearing your feedback and working closely with you to continue improving the quality and impact of CP Program research.
With best wishes for your health, safety, and success,
Stephen K. Burley, M.D., D.Phil. and X.F. Steven Zheng, Ph.D.
Co-Leaders, Cancer Pharmacology Program
Rutgers Cancer Institute of New Jersey
|
|
Enver Izgu, PhD was awarded a NIBIB grant entitled "Activity-Based Aptamers as Bioimaging Tools for Probing Organics, Inorganics, and Enzymes"" Grant Number: 1R21EB029548-01 Term: 06/01/2020 - 03/31/2022. Annual Direct Costs: $200,000
Jeroen Tromp, PhD was awarded a NSF grant entitled "PFI-TT: High-Resolution Medical Imaging Using Ultrasound" Grant Number: 1941241 Term: 05/01/2020 - 10/31/2021. Annual Direct Costs: $250,000
Martin L. Yarmush, MD, PhD, Paul and Mary Monroe Endowed Chair and Distinguished Professor, Department of Biomedical Engineering, has been named the 2020 recipient of the University’s Daniel Gorenstein Memorial Award on April 20th, 2020.
Steven K. Burley, MD, DPhil spearheaded efforts in establishing and organizing Rutgers IQB COVID-19 working groups, which are composed of Rutgers faculty including CP Program members, to tackle broad range of COVID-19 challenges ranging from COVID-19 biology to novel drug discovery to vaccine development.
Shengkan (Victor) Jin, PhD developed a novel CRISPR base editing technology that can be used for treatment of diseases such as cancer. More information can be found here.
|
|
Al-Zubaydi F, Gao D, Kakkar D, Li S, Adler D, Holloway J, Szekely Z, Gu Z, Chan N, Kumar S, Love S, Sinko PJ. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. J Control Release. 2020;323:71-82. Epub 2020/04/18. doi: 10.1016/j.jconrel.2020.04.016. PubMed PMID: 32302762.
Burley SK. How to help the free market fight coronavirus. Nature. 2020;580(7802):167. Epub 2020/03/27. doi: 10.1038/d41586-020-00888-7. PubMed PMID: 32210376.
Burton AJ, Haugbro M, Gates LA, Bagert JD, Allis CD, Muir TW. In situ chromatin interactomics using a chemical bait and trap approach. Nat Chem. 2020;12(6):520-7. Epub 2020/05/31. doi: 10.1038/s41557-020-0474-8. PubMed PMID: 32472103; PMCID: PMC7331920.
García-Cañaveras JC, Lancho O, Ducker GS, Ghergurovich JM, Xu X, da Silva-Diz V, Minuzzo S, Indraccolo S, Kim H, Herranz D, Rabinowitz JD. SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. Leukemia. 2020. Epub 2020/05/10. doi: 10.1038/s41375-020-0845-6. PubMed PMID: 32382081.
Tang FHF, Davis D, Arap W, Pasqualini R, Staquicini FI. Eph receptors as cancer targets for antibody-based therapy. Adv Cancer Res. 2020;147:303-17. Epub 2020/07/01. doi: 10.1016/bs.acr.2020.04.007. PubMed PMID: 32593404.
|
|
Clinical Investigations &
Precision Therapeutics
|
|
Andrew Evens, DO, MSc was honored with being elected to the Board of Trustees for the Leukemia and Lymphoma Society, New Jersey Chapter.
Coral Omene MD, PhD and Michael Gatza, PhD were awarded a Translational Research Pilot Award from The Rutgers Cancer Institute of New Jersey, through support from the CCSG and ORED entitled “Investigating the therapeutic impact of CPT1A in hormone receptor positive breast cancer”. Term: 01/27/20 – 01/26/2021. Annual Direct Costs: $50,000.
|
|
Andrew Evens, DO, MSc presented "Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine" at the Annual Meeting Education Sessions held December, 2019. Blood (ASH).
Andrew Evens, DO, MSc presented at the Mantle Cell Lymphoma Roundtable for MDedge Hematology & Oncology (via Medscape) held January 27, 2020 in New York, New York.
Andrew Evens, DO, MSc presented at the Rutgers CINJ led event ASH Review 2019 (via Leukemia & Lymphoma Society) held February 13, 2020 in Spring Lake, New Jersey.
Andrew Evens, DO, MSc presented on updates in Hodgkin Lymphoma at Challenging Cases® in Hematology event held February 22, 2020 in New York, New York.
Andrew Evens, DO, MSc presented "Current and Future Treatment of Hodgkin Lymphoma" at Opinions in Hematologic Malignancies: Winter National Summit held February 28, 2020 in Banff, Canada.
H.Richard Alexander, MD gave Grand Rounds to the Department of Surgery at New York University where he presented "Surgical Management of Peritoneal Metastases from Colorectal Cancer: The Role of Cytoreduction and HIPEC" held January, 2020.
|
|
Allen PB, Ayers A, Behera M, Evens AM, Flowers C. A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. Leuk Lymphoma. 2020:1-10. Epub 2020/02/28. doi: 10.1080/10428194.2020.1731497. PubMed PMID: 32102579.
Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020;85(3):621-6. Epub 2020/02/10. doi: 10.1007/s00280-020-04037-9. PubMed PMID: 32036412; PMCID: PMC7036073.
Bates JE, Parikh RR, Mendenhall NP, Morris CG, Hoppe RT, Constine LS, Hoppe BS. Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2020. Epub 2020/03/17. doi: 10.1016/j.ijrobp.2020.02.642. PubMed PMID: 32173399.
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol. 2020. Epub 2020/02/18. doi: 10.1016/j.euo.2020.01.005. PubMed PMID: 32063492.
Chang GJ, You YNY, Russell CA, Tierno MB, Turner M, Bennett JP, Lau A, Hochster HS. Young-Onset Colon Cancer and Recurrence Risk By Gene Expression. J Natl Cancer Inst. 2020. Epub 2020/02/11. doi: 10.1093/jnci/djaa019. PubMed PMID: 32040172.
Contractor T, Clausen R, Harris G, Rosenfeld J, Carpizo D, Tang L, Harris C. IGF2 drives formation of ileal neuroendocrine tumors in patients and mice. Endocr Relat Cancer. 2020. Epub 2020/01/18. doi: 10.1530/erc-19-0505. PubMed PMID: 31951591.
Evens AM, Carter J, Loh KP, David KA. Management of older Hodgkin lymphoma patients. Hematology Am Soc Hematol Educ Program. 2019;2019(1):233-42. Epub 2019/12/07. doi: 10.1182/hematology.2019000028. PubMed PMID: 31808898; PMCID: PMC6913478.
Jabbour SK, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB, 2nd, Bradley JD, Aisner J, Malhotra J. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2020. Epub 2020/02/23. doi: 10.1001/jamaoncol.2019.6731. PubMed PMID: 32077891; PMCID: PMC7042914.
Kharofa J, Hallemeier CL, Huguet F, Anker CJ, Buckstein MH, Tait D, Olsen JR, Jabbour SK. Gastrointestinal Cancers: Moving the Needle for Rectal, Gastroesophageal, Pancreaticobiliary, and Liver Cancers. Int J Radiat Oncol Biol Phys. 2020;106(4):653-62. Epub 2020/02/25. doi: 10.1016/j.ijrobp.2019.12.011. PubMed PMID: 32092335.
Llanos AAM, Lin Y, Chen W, Yao S, Norin J, Chekmareva MA, Omene C, Cong L, Omilian AR, Khoury T, Hong CC, Ganesan S, Foran DJ, Higgins M, Ambrosone CB, Bandera EV, Demissie K. Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype. Breast Cancer Res. 2020;22(1):18. Epub 2020/02/13. doi: 10.1186/s13058-020-1256-3. PubMed PMID: 32046756; PMCID: PMC7014630.
Loh JW, Guccione C, Di Clemente F, Riedlinger G, Ganesan S, Khiabanian H. All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data. Bioinformatics. 2020;36(7):2173‐2180. doi:10.1093/bioinformatics/btz865
Omene C, Ma L, Moore J, Ouyang H, Illa-Bochaca I, Chou W, Patel MS, Sebastiano C, Demaria S, Mao JH, Karagoz K, Gatza ML, Barcellos-Hoff MH. Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention. Cancer Immunol Res. 2020;8(2):217-29. Epub 2019/12/14. doi: 10.1158/2326-6066.Cir-19-0253. PubMed PMID: 31831632; PMCID: PMC7002223.
Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The Cytoreductive prostatectomy in Metastatic Prostate Cancer: What the individual trials are hoping to answer. BJU Int. 2020. Epub 2020/03/17. doi: 10.1111/bju.15055. PubMed PMID: 32176456.
Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK. First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. Br J Haematol. 2020. Epub 2020/02/25. doi: 10.1111/bjh.16525. PubMed PMID: 32090325.
Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precision Oncology. 2020(4):442-65. doi: 10.1200/po.19.00345.
Tan XL, E JY, Lin Y, Rebbeck TR, Lu SE, Shang M, Kelly WK, D'Amico A, Stein MN, Zhang L, Jang TL, Kim IY, Demissie K, Ferrari A, Lu-Yao G. Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer. Cancer Med. 2020. Epub 2020/02/09. doi: 10.1002/cam4.2862. PubMed PMID: 32035002.
Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020:Jco1903292. Epub 2020/02/26. doi: 10.1200/jco.19.03292. PubMed PMID: 32097092.
Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L, Hamada K, Berlin JD, Saltz LB. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. Clin Cancer Res. 2020. Epub 2020/01/12. doi: 10.1158/1078-0432.Ccr-19-2743. PubMed PMID: 31924737.
Wu P, Wang X, Ma Y, Xu X, Liu W, Sheng Z, Chen M, Zhou R, Zhang K, Goodin S, Zheng X, Li D. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorg Chem. 2020;101:104022. Epub 2020/07/01. doi: 10.1016/j.bioorg.2020.104022. PubMed PMID: 32599367.
Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argiles G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020;31(1):88-95. Epub 2020/01/09. doi: 10.1016/j.annonc.2019.10.005. PubMed PMID: 31912801.
|
|
Genomic Instability & Cancer Genetics |
|
Michael Verzi, PhD was awarded a NIDDK grant entitled "Mechanisms of Intestinal Epithelial Differentiation" Grant Number: 1R01DK121915-01A1 Term: 07/16/2020 - 06/30/2024. Annual Direct Costs: $261,000
Sharon Pine, PhD was awarded a NCI grant entitled "Discovery and Therapeutic Targeting of Biological Determinants of Lung Cancer Health Disparities" Grant Number: 1R01CA239093-01A1 Term: 05/15/2020 - 04/30/2025. Annual Direct Costs: $267,927
Subhajyoti De, PhD was awarded an Exploratory/Development grant by NIH for the project titled "Interference of Tumor Growth Dynamics Using Genomic Data". Grant Number: 1R21CA248122-01 Term: 05/15/2020 - 04/30/2022. Annual Direct Costs: $140,250.
Zhongren (David) Zhou, MD, PhD was awarded a NIDDK grant entitled "Gene Therapy for Gerd-Associated Esophageal Epithelial Barrier Dysfunction" Grant Number: 1R01DK120680-01A1 Term: 04/15/2020 - 03/31/2023. Annual Direct Costs: $117,939
|
|
Hossein Khiabanian, PhD presented "Distinct Genomic Landscape of Hematopoietic Cells Admixed in Solid Tumor Microenvironment" at the Regional Cancer Centers Conference, Columbia University, held December 2019.
Reglero C, Dieck C, Loh J-W, Khiabanian H, Ferrando A. Post-translational Mechanisms of NT5C2 Activation as Non-Genetic Drivers of Chemotherapy Resistance in Relapsed ALL. Proceedings of the 61st ASH Annual Meeting, Orlando FL. Blood (2019) 134 (Supplement_1): 728.
Kritharis A, Kaur S, Loh J-W, Hadigol M, Khiabanian H, Strair R. Deep DNA Sequencing Identifies Small Mutations in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Analysis of Intratumor Genomic Heterogeneity for Prediction of Disease Relapse. Proceedings of the 61st ASH Annual Meeting, Orlando, FL. Blood (2019)
|
|
Loh JW, Guccione C, Di Clemente F, Riedlinger G, Ganesan S, Khiabanian H. All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data. Bioinformatics. 2020;36(7):2173-80. Epub 2019/11/22. doi: 10.1093/bioinformatics/btz865. PubMed PMID: 31750888; PMCID: PMC7141867.
Lu H, Ye C, Feng X, Liu J, Bhaumik M, Xia B, Liu C, Shen Z. Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice. Am J Pathol. 2020;190(6):1175-87. Epub 2020/03/24. doi: 10.1016/j.ajpath.2020.01.020. PubMed PMID: 32201259; PMCID: PMC7280756.
Malhotra J, Jabbour SK, Pine S. Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors. Transl Lung Cancer Res. 2019;8(Suppl 4):S347-s50. Epub 2020/02/11. doi: 10.21037/tlcr.2019.05.04. PubMed PMID: 32038912; PMCID: PMC6987361.
Panda A, Yadav A, Yeerna H, Singh A, Biehl M, Lux M, Schulz A, Klecha T, Doniach S, Khiabanian H, Ganesan S, Tamayo P, Bhanot G. Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples. Nucleic Acids Res. 2020;48(13):7079-98. Epub 2020/06/12. doi: 10.1093/nar/gkaa485. PubMed PMID: 32525984; PMCID: PMC7367157.
Singh VK, Rastogi A, Hu X, Wang Y, De S. Mutational signature SBS8 predominantly arises due to late replication errors in cancer. Commun Biol. 2020;3(1):421. Epub 2020/08/05. doi: 10.1038/s42003-020-01119-5. PubMed PMID: 32747711; PMCID: PMC7400754.
Yue X, Wu F, Li Y, Liu J, Boateng M, Mandava K, Zhang C, Feng Z, Gao J, Hu W. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis. Cell Cycle. 2020;19(11):1338-51. Epub 2020/04/11. doi: 10.1080/15384101.2020.1749790. PubMed PMID: 32275841.
Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020. Epub 2020/07/30. doi: 10.1093/jmcb/mjaa040. PubMed PMID: 32722796.
|
|
Basic Research & Clinical Research Programs
Rutgers Cancer Institute of New Jersey
|
|
|
|
|
|
|
